These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 36147581)
21. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751 [TBL] [Abstract][Full Text] [Related]
22. Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version. Carlborg L Contraception; 1983 May; 27(5):439-52. PubMed ID: 6349925 [TBL] [Abstract][Full Text] [Related]
23. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency. Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796 [TBL] [Abstract][Full Text] [Related]
24. Oral contraceptives and cognition: A role for ethinyl estradiol. Beltz AM; Hampson E; Berenbaum SA Horm Behav; 2015 Aug; 74():209-17. PubMed ID: 26122296 [TBL] [Abstract][Full Text] [Related]
27. Estrogen and progestin components of oral contraceptives: relationship to vascular disease. Carr BR; Ory H Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222 [TBL] [Abstract][Full Text] [Related]
28. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation. Letterie GS Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249 [TBL] [Abstract][Full Text] [Related]
29. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546 [TBL] [Abstract][Full Text] [Related]
30. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750 [TBL] [Abstract][Full Text] [Related]
31. Clinical experience with a triphasic oral contraceptive ('Trinordiol') in young women. Gaspard UJ; Deville JL; Dubois M Curr Med Res Opin; 1983; 8(6):395-404. PubMed ID: 6406157 [TBL] [Abstract][Full Text] [Related]
32. Changes in insulin receptors during oral contraception. De Pirro R; Forte F; Bertoli A; Greco AV; Lauro R J Clin Endocrinol Metab; 1981 Jan; 52(1):29-33. PubMed ID: 7451643 [TBL] [Abstract][Full Text] [Related]
33. Ovarian activity suppression by two different low-dose triphasic oral contraceptives. van der Does J; Exalto N; Dieben T; Bennink HC Contraception; 1995 Dec; 52(6):357-61. PubMed ID: 8749599 [TBL] [Abstract][Full Text] [Related]